Target (TGT) Reaches $77.05 After 3.00% Up Move; Recro Pharma, Inc. (REPH) Had 10 Analysts Last Week

June 21, 2018 - By Linda Rogers

Target Corporation (NYSE:TGT) Logo

The stock of Target Corporation (NYSE:TGT) is a huge mover today! The stock increased 2.20% or $1.66 during the last trading session, reaching $77.05. About 1.57 million shares traded. Target Corporation (NYSE:TGT) has risen 31.38% since June 21, 2017 and is uptrending. It has outperformed by 18.81% the S&P500. Some Historical TGT News: 06/03/2018 – TARGET SEES OPERATING MARGINS DECLINING 60BPS-80BPS IN 1Q; 14/05/2018 – Target Closes Above 50-Day Moving Average: Technicals; 06/03/2018 – Target: 4Q Traffic Growth Reflects Healthy Increases in Stores, Digital Channels; 06/03/2018 – TARGET RAISING MINIMUM HOURLY WAGE TO $12 IN 2018; 29/03/2018 – USDA: Target Corporation Recalls Frozen Ready-To-Eat and Non-Ready-To-Eat Meat And Poultry Products due to Possible Temperature; 23/03/2018 – Baltimore Business: Source denies report that Harris Teeter parent, Target are discussing merger; 06/03/2018 – Target’s Same-Store Sales Surpass Expectations; 23/05/2018 – TARGET CORP TGT.N FY SHR VIEW $5.28 — THOMSON REUTERS l/B/E/S; 06/03/2018 – Target 4Q Average Transaction Amount Rose 0.4%; 06/03/2018 – TARGET CORP TGT.N SEES FY 2018 ADJUSTED SHR $5.15 TO $5.45The move comes after 8 months positive chart setup for the $41.08 billion company. It was reported on Jun, 21 by Barchart.com. We have $79.36 PT which if reached, will make NYSE:TGT worth $1.23B more.

Among 10 analysts covering Recro Pharma (NASDAQ:REPH), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Recro Pharma had 19 analyst reports since August 25, 2015 according to SRatingsIntel. Piper Jaffray maintained Recro Pharma, Inc. (NASDAQ:REPH) on Tuesday, July 25 with “Buy” rating. The rating was initiated by H.C. Wainwright on Wednesday, September 2 with “Buy”. The stock of Recro Pharma, Inc. (NASDAQ:REPH) has “Buy” rating given on Friday, September 16 by Roth Capital. The stock has “Overweight” rating by Piper Jaffray on Monday, December 19. The firm earned “Buy” rating on Monday, October 3 by Brean Capital. Aegis Capital initiated it with “Buy” rating and $21 target in Monday, November 14 report. TH Capital initiated Recro Pharma, Inc. (NASDAQ:REPH) on Friday, September 16 with “Buy” rating. The firm has “Hold” rating given on Tuesday, August 25 by Zacks. The firm has “Buy” rating given on Tuesday, February 13 by Oppenheimer. The stock of Recro Pharma, Inc. (NASDAQ:REPH) has “Buy” rating given on Wednesday, February 28 by Piper Jaffray. See Recro Pharma, Inc. (NASDAQ:REPH) latest ratings:

24/05/2018 Broker: Janney Capital Rating: Buy New Target: $11.0000
10/05/2018 Broker: Oppenheimer Rating: Buy New Target: $19.0000 Maintain
19/04/2018 Broker: Berenberg Rating: Buy New Target: $21.2500 Initiate
28/02/2018 Broker: Piper Jaffray Rating: Buy New Target: $12.0 Maintain
13/02/2018 Broker: Oppenheimer Rating: Buy New Target: $19.0 Initiate

More notable recent Target Corporation (NYSE:TGT) news were published by: Seekingalpha.com which released: “At What Point Do I Sell Target?” on June 14, 2018, also Streetinsider.com with their article: “Target (TGT) call put ratio 3.6 calls to 1 put as shares rally 2% after Supreme Court rules states can require internet tax …” published on June 21, 2018, Seekingalpha.com published: “Target continues to break out” on June 05, 2018. More interesting news about Target Corporation (NYSE:TGT) were released by: Seekingalpha.com and their article: “Traffic strong at Target” published on May 23, 2018 as well as Seekingalpha.com‘s news article titled: “Target: Could Be Worse To Come” with publication date: May 24, 2018.

Among 29 analysts covering Target Corporation (NYSE:TGT), 11 have Buy rating, 3 Sell and 15 Hold. Therefore 38% are positive. Target Corporation had 92 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of Target Corporation (NYSE:TGT) earned “Hold” rating by Robert W. Baird on Tuesday, January 9. The firm has “Neutral” rating by Susquehanna given on Friday, February 10. JP Morgan maintained the stock with “Neutral” rating in Thursday, May 19 report. Jefferies maintained the stock with “Hold” rating in Tuesday, June 20 report. The stock has “Hold” rating by Stifel Nicolaus on Wednesday, August 9. Deutsche Bank maintained the shares of TGT in report on Monday, August 17 with “Hold” rating. Citigroup downgraded the shares of TGT in report on Wednesday, June 21 to “Neutral” rating. The firm has “Outperform” rating by Telsey Advisory Group given on Wednesday, January 18. The rating was upgraded by Vetr on Tuesday, September 8 to “Strong-Buy”. The stock of Target Corporation (NYSE:TGT) has “Outperform” rating given on Thursday, August 18 by Telsey Advisory Group.

Target Corporation operates as a general merchandise retailer. The company has market cap of $41.08 billion. It offers household essentials, including pharmacy, beauty, personal care, baby care, cleaning, and paper products; dry grocery, dairy, frozen food, beverages, candy, snacks, deli, bakery, meat, produce, and pet supplies; and apparel for women, men, boys, girls, toddlers, infants, and newborns, as well as intimate apparel, jewelry, accessories, and shoes. It has a 14.45 P/E ratio. The firm also provides home furnishings and décor, such as furniture, lighting, kitchenware, small appliances, home décor, bed and bath, home improvement, and automotive products, as well as seasonal merchandise, such as patio furniture and holiday décor; music, movies, books, computer software, sporting goods, and toys, as well as electronics, such as video game hardware and software.

Analysts await Target Corporation (NYSE:TGT) to report earnings on August, 15. They expect $1.39 earnings per share, up 13.01% or $0.16 from last year’s $1.23 per share. TGT’s profit will be $741.06 million for 13.86 P/E if the $1.39 EPS becomes a reality. After $1.32 actual earnings per share reported by Target Corporation for the previous quarter, Wall Street now forecasts 5.30% EPS growth.

More notable recent Recro Pharma, Inc. (NASDAQ:REPH) news were published by: Prnewswire.com which released: “SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Recro …” on June 20, 2018, also Seekingalpha.com with their article: “Recro Pharma: Oversold?” published on May 26, 2018, Globenewswire.com published: “Recro Pharma Receives Complete Response Letter from the FDA” on May 24, 2018. More interesting news about Recro Pharma, Inc. (NASDAQ:REPH) were released by: Globenewswire.com and their article: “REPH LOSS NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Recro Pharma, Inc …” published on June 02, 2018 as well as Globenewswire.com‘s news article titled: “Pomerantz Law Firm Announces the Filing of a Class Action against Recro Pharma, Inc. and Certain Officers – REPH” with publication date: May 31, 2018.

The stock decreased 0.29% or $0.015 during the last trading session, reaching $5.165. About 49,164 shares traded. Recro Pharma, Inc. (NASDAQ:REPH) has declined 32.73% since June 21, 2017 and is downtrending. It has underperformed by 45.30% the S&P500. Some Historical REPH News: 24/05/2018 – FDA declines to approve Recro Pharma’s non-opioid pain shot; 24/05/2018 – RECRO PHARMA INC – INTEND TO REQUEST A MEETING WITH FDA AS SOON AS POSSIBLE TO DISCUSS POINTS RAISED IN CRL; 18/05/2018 – Recro Pharma Closes Above 50-Day Moving Average: Technicals; 24/05/2018 – RECRO PHARMA: FDA UNABLE TO APPROVE APPLICATION IN CURRENT FORM; 24/05/2018 – Recro Pharma to Request a Meeting With the FDA as Soon as Possible; 16/04/2018 – Recro Pharma to Present IV Meloxicam Data at the 43rd Annual Regional Anesthesiology and Acute Pain Medicine Meeting; 10/05/2018 – Sphera Funds Buys New 1.8% Position in Recro Pharma; 24/05/2018 – RECRO PHARMA GETS COMPLETE RESPONSE LETTER FROM FDA; 24/05/2018 – Recro Pharma: FDA Is Unable to Approve the New Drug Application for IV Meloxicam in Its Current Form; 24/05/2018 – RECRO PHARMA INC – CRL STATES DATA FROM AD HOC ANALYSES & SELECTIVE SECONDARY ENDPOINTS SUGGEST ANALGESIC EFFECT DOES NOT MEET EXPECTATIONS OF FDA

Since January 2, 2018, it had 0 insider buys, and 7 sales for $3.70 million activity. 38,810 shares were sold by SCP Vitalife Partners II LP, worth $344,688. 188,000 shares valued at $1.09 million were sold by Broadfin Healthcare Master Fund Ltd on Thursday, May 24. Shares for $115,139 were sold by SCP Vitalife Partners (Israel) II – L.P. on Tuesday, January 2. Shares for $78,347 were sold by Berelowitz Michael on Friday, March 9.

Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company has market cap of $105.92 million. The Company’s lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain. It currently has negative earnings. The firm also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain.

Recro Pharma, Inc. (NASDAQ:REPH) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Linda Rogers

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: